LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today reported its September 30, 2007 cash balance and its financial results for the third quarter and nine months ended September 30, 2007. The Company’s cash, cash equivalents and short-term investments as of September 30, 2007 were approximately $29.4 million, as compared to approximately $11.5 million on December 31, 2006. The Company’s cash burn rate in the last quarter of 2007 is expected to be approximately $750,000 per month as its LibiGel® (transdermal testosterone gel) Phase III clinical development progresses for the treatment of female sexual dysfunction.
